Foundation Medicine expands collaboration with Bristol Myers

Foundation Medicine announced an expansion to its collaboration with Bristol Myers (BMY) Squibb to develop FoundationOneCDx as a next-generation sequencing-based companion diagnostic to identify patients with homozygous MTAP deletion in multiple indications for an investigational targeted therapy. The expansion broadens Foundation Medicine’s longstanding relationship in advancing biomarker-driven therapies with Bristol Myers Squibb. Homozygous deletion is a major cause of MTAP deficiency. Copy number calling can have low signal-to-noise ratio, making the alterations challenging to accurately identify. FoundationOne CDx is a tissue-based next-generation sequencing test approved by the FDA to detect copy number loss. Accurate reporting of homozygous deletion can help identify eligible patients for targeted therapies.